## UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 208.1004US

Total Pages in this Submission 89

#### TO THE ASSISTANT COMMISSIONER FOR PATENTS

**Box Patent Application** Washington, D.C. 20231

invention entitled:

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent applicati

invention entitled.						
LORATADINE TRANSDERMAL DEVICE & METHODS	30 <b>868</b> U					
and invented by:						
Lino TAVARES, Ihor SHEVCHUK, Mark ALFONSO, Geraldine MARCENYAC and Kirti H. VALI	A					
	j					
If a CONTINUATION APPLICATION, check appropriate box and supply the requisite information:						
☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.:						
Which is a:						
☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.:						
Which is a:						
Continuation Divisional Continuation-in-part (CIP) of prior application No.:						
Enclosed are:						
Application Elements						
1.   Filing fee as calculated and transmitted as described below						
2. 🗵 Specification having						
pages and making me terming.						
a. 🗵 Descriptive Title of the Invention						
b. Cross References to Related Applications (if applicable)						
c.   Statement Regarding Federally-sponsored Research/Development (if applicable)						
d.  Reference to Microfiche Appendix (if applicable)						
e. 🗵 Background of the Invention						
f. 🗵 Brief Summary of the Invention						
g. 🗵 Brief Description of the Drawings (if drawings filed)						
h. 🗵 Detailed Description						
i. 🗵 Claim(s) as Classified Below						
j. 🛛 Abstract of the Disclosure	- •.					

# UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. **208.1004US** 

Total Pages in this Submission 89

### **Application Elements (Continued)**

3.	X	Drawing(s) (when necessary as prescribed by 35 USC 113)					
	a.	□ Forma	al	Number of Sheets14			
	b.	☐ Inform	al	Number of Sheets			
4.		Oath or Declaration					
	a.	. □ Newly executed (original or copy) □ Unexecuted					
	b.	Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only)					
	C.	With Power of Attorney  Without Power of Attorney					
	d.	DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. 1.63(d)(2) and 1.33(b).					
5.		Incorporation By Reference (usable if Box 4b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.					
6.		Computer Program in Microfiche (Appendix)					
7.		Nucleotide and/or Amino Acid Sequence Submission (if applicable, all must be included)					
	a.	☐ Paper Copy					
	b.	☐ Computer Readable Copy (identical to computer copy)					
	C.	☐ Staten	nent Verifyin	g Identical Paper and Computer Readable Copy			
	Accompanying Application Parts						
8.		Assignment Papers (cover sheet & document(s))					
9.		37 CFR 3.73(B) Statement (when there is an assignee)					
10.		English Translation Document (if applicable)					
11.		Information Disclosure Statement/PTO-1449   Copies of IDS Citations					
12.		Preliminary Amendment					
13.	X	Acknowledgment postcard					
14.	×	2 Certificate of Mailing					
		☐ First C	lass 🛚	Express Mail (Specify Label No.): EL 914 493 075 US			

# UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 208.1004US

Total Pages in this Submission 89

	Accompanying Application Parts (Continued)						
15.		Certified Copy of Priority Document(s) (if foreign priority is claimed)					
16.	X	Additional Enclosures (please identify below):					
		Letter re: Priority from Provisional Application.					
		Degree That Application Not De Dublished Durawant To 25 U.S.C. 422(b)(2)					
		Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)					
17.		Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.					

#### Warning

An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.

# UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. **208.1004US** 

Total Pages in this Submission 89

#### Fee Calculation and Transmittal

CLAIMS AS FILED							
For	#Filed	#Allowed	#Extra	Rate		Fee	
Total Claims	45	- 20 =	25	× \$18.00		\$450.00	
ndep. Claims	5	- 3 =	2	x \$84.00		\$168.00	
Multiple Dependent	Claims (check	if applicable)				\$0.00	
BASIC FEE						\$740.00	
OTHER FEE (specify purpose)						\$0.00	
				TOTA	L FILING FEE	\$1,358.00	
□ A check in the amount of to cover the filing fee is enclosed. □ The Commissioner is hereby authorized to charge and credit Deposit Account No. as described below. A duplicate copy of this sheet is enclosed. □ Charge the amount of as filing fee. □ Credit any overpayment. □ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17. □ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).							

Page 4 of 4

Dated: October 23, 2001

CC:

23280

PATENT TRADEMARK OFFICE

Robert J. Paradiso

Davidson, Davidson & Kappel, LLC 485 Seventh Avenue, 14th Floor New York, New York 10018

	·						
CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)  Docket No.							
Applicant(s): Line TAV		208.1004US					
Applicant(o).							
Serial No.	Serial No. Filing Date Examiner		Group Art Unit				
To be Assigned	To be Assigned Herewith To be Assigned To be Assigned						
Invention: LORATADII	NE TRANSDERMAL DEVICE &	METHODS					
	e following correspondence:  olication and Accompanying Docu						
	(Identify type	of correspondence)					
is being deposited with	h the United States Postal Servi	ce "Express Mail Post Office to Ad	dressee" service under				
37 CFR 1.10 in an env	velone addressed to: The Assista	nt Commissioner for Patents, Wasl	nington, D.C. 20231 on				
(Date							
October 2 (Date)		Benjamin S. DiMar	rco				
		(Typed or Printed Name of Person Mailin					
Sagra-							
	•	EL 914 493 075 U	S				
कार कार इ. ट.		("Express Mail" Mailing Label					
Note: Each paper must have its own certificate of mailing.							